LA Improves the Prognosis of Patients With ICVD

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age35-65
SponsorHuaqiu Zhang

About this trial

Ischemic cerebrovascular disease will cause serious harm to the life and safety of patients, and the treatment prognosis is poor. Numerous clinical trials have demonstrated that probiotics can improve cognitive function in people under multimodal. We have previously found that Lactobacillus acidophilus administration could improve cognitive impairment in MCAO and BCAS mice. Therefore, Based on the above research background and the basis of previous studies, we believe that the administration of Lactobacillus acidophilus solid drink (pure Lactobacillus acidophilus strain) can improve the cognitive function of patients with cerebral ischemia through the "brain-gut axis".

Eligibility criteria

Qualifiers

Between 35 and 65 years old;

Han nationality;

Diagnosed as ischemic cerebrovascular disease with mild to moderate symptoms;

Can communicate normally, complete neuropsychological tests independently, and sign informed consent;

Disqualifiers

previous dementia;

hearing or visual impairment;

Drugs that may or are known to influence cognitive abuse;

alcohol addiction;

Trial design

Treatments tested in this trial

  • Lactobacillus acidophilus
  • Maltodextrin

Treatment groups

236 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Huaqiu Zhang

Lead sponsor

Tongji Hospital

Sponsor institution